Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles VaccineCollaboration Agreement • October 25th, 2022
Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology Clinical trials are expected to start in the second half of 2022 BioNTech will receive $225 million upfront, including an upfront cash payment of $75 million and an equity investment of
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles VaccineCollaboration Agreement • October 25th, 2022
Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology Clinical trials are expected to start in the second half of 2022 BioNTech will receive $225 million upfront, including an upfront cash payment of $75 million and an equity investment of
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles VaccineCollaboration Agreement • October 25th, 2022
Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology Clinical trials are expected to start in the second half of 2022 BioNTech will receive $225 million upfront, including an upfront cash payment of $75 million and an equity investment of
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles VaccineCollaboration Agreement • October 25th, 2022
Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology Clinical trials are expected to start in the second half of 2022 BioNTech will receive $225 million upfront, including an upfront cash payment of $75 million and an equity investment of
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles VaccineCollaboration Agreement • January 5th, 2022
Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world